NCT04850846: Phase 2: Investigation of Metformin for the Prevention of Progression of Precursor MM
Updated: May 23, 2022
NCT04850846: Phase 2: Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma
Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma
The purpose of this research is to understand whether the drug metformin could be used in the future to help prevent patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) from developing multiple myeloma.
The names of the study drug involved in this study is:
Metformin, extended release
Placebo (a pill that has no active ingredients)
Sponsor:
Dana-Farber Cancer Institute
Collaborator:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT04850846
Official Title: A Randomized Placebo-Controlled Phase 2 Study of Metformin for the Prevention of Progression of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
First Posted: April 20, 2021
Click here to see details on ClinicalTrials.gov
Drug: Metformin XR
Other: Placebo
Locations
United States, Massachusetts
United States, New Hampshire